A Clinical Study of the Efficacy and Safety of Corticosteroids for Cancer-induced Neuropathic Pain.

A Prospective, Multicenter, Observational Study of the Efficacy and Safety of Corticosteroids for Tumor-Induced Central and Peripheral Neuropathic Pain in Cancer Patients. - A Prospective Observational Study of the Efficacy and Safety of Corticosteroids for Tumor-Induced Neuropathic Pain.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040584

Enrollment

200

Registered

2020-06-01

Start date

2020-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients over 20 years old Patients who have been diagnosed with cancer. Patients in the hospital Patients with cancer pain (Brief Pain Inventory short form; worst pain intensity score of 4 or higher in the past 24 hours) Patients will be scheduled to receive regular corticosteroids for the treatment of cancer-induced neuropathic pain

Exclusion criteria

Exclusion criteria: Patients whose physicians consider it inappropriate to participate in the research. Patients who are pregnant, lactating, or may be pregnant. Patients with diabetes who have poor glycemic control who need additional insulin injections Patients with an infection-caused fever of 38 degrees or higher Patients undergoing treatment for an active gastrointestinal ulcer Patients with diagnoses of hematological malignancy Serious adverse events due to corticosteroid in the past Patients who started a new anticancer treatment with a molecularly targeted agency or immune checkpoint inhibitor within 2 weeks, or are scheduled to start the treatment within 1 week Patients were administrated corticosteroids more than the scheduled dose on the day before the start of treatment Patients scheduled to administrate corticosteroids more than its regular doses in one week for the treatment of adverse effects by anticancer therapy Patients who are scheduled to receive surgery for the pain control in a week

Design outcomes

Primary

Measure	Time frame
To compare the difference of pain intensity (worst pain in 24 hours) between baseline, 72 hours later and 168 hours later.	—

Countries

Japan

Contacts

Public ContactKeita Tagami

Tohoku University Graduate School of Medicine Palliative Medicine

keita.tagami.d7@tohoku.ac.jp0227177366

Outcome results